Tirzepatide outpacing Wegovy in the obesity space
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
Could Trump Make A Big Weight Loss Drug Deal?
Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...
West Virginia patients are left in limbo over changing insurance coverage of obesity medications
While West Virginia's employee health insurance program covers drugs like Ozempic for people with type 2 diabetes, officials ...
FiercePharma11h
Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData
Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it ...
GLP-1 Drugs For Weight Loss Aren’t Cost-Saving Yet
Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...
24/7 Wall St2h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
FiercePharma1h
Lilly looks to 'protect its interests' by moving to join FDA lawsuit over compounded tirzepatide
After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...
clinicaltrialsarena7h
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.